Brindley, P.J., M. Bachini, S.I. Ilyas, et al. 2021. Cholangiocarcinoma. Nature Reviews Disease Primers 7 (1): 65. https://doi.org/10.1038/s41572-021-00300-2.

Article  PubMed  PubMed Central  Google Scholar 

Dodson, R.M., M.J. Weiss, D. Cosgrove, et al. 2013. Intrahepatic cholangiocarcinoma: management options and emerging therapies. Journal of the American College of Surgeons 217 (4): 736-750.e4. https://doi.org/10.1016/j.jamcollsurg.2013.05.021.

Article  PubMed  Google Scholar 

Jarnagin, W.R., Y. Fong, R.P. DeMatteo, et al. 2001. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Annals of Surgery 234 (4): 507–17. https://doi.org/10.1097/00000658-200110000-00010.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong, J.C., C.M. Jones, J.P. Duffy, et al. 2011. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Archives of Surgery 146 (6): 683–9. https://doi.org/10.1001/archsurg.2011.116.

Article  PubMed  Google Scholar 

Schumacher, T.N., and R.D. Schreiber. 2015. Neoantigens in cancer immunotherapy. Science 348 (6230): 69–74. https://doi.org/10.1126/science.aaa4971.

Article  ADS  CAS  PubMed  Google Scholar 

Sahin, U., E. Derhovanessian, M. Miller, et al. 2017. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547 (7662): 222–226. https://doi.org/10.1038/nature23003.

Article  ADS  CAS  PubMed  Google Scholar 

Ott, P.A., S. Hu-Lieskovan, B. Chmielowski, et al. 2020. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183 (2): 347-362.e24. https://doi.org/10.1016/j.cell.2020.08.053.

Article  CAS  PubMed  Google Scholar 

Wang, A.Z., R. Langer, and O.C. Farokhzad. 2012. Nanoparticle delivery of cancer drugs. Annual Review of Medicine 63: 185–98. https://doi.org/10.1146/annurev-med-040210-162544.

Article  CAS  PubMed  Google Scholar 

Shao, J., Q. Liu, J. Shen, et al. 2022. Advanced pancreatic cancer patient benefit from personalized neoantigen nanovaccine based immunotherapy: a case report. Fronties in Immunology 13: 799026. https://doi.org/10.3389/fimmu.2022.799026.

Article  CAS  Google Scholar 

Weber, S.M., D. Ribero, E.M. O’Reilly, N. Kokudo, M. Miyazaki, and T.M. Pawlik. 2015. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford) 17 (8): 669–80. https://doi.org/10.1111/hpb.12441.

Article  PubMed  Google Scholar 

Hyder, O., I. Hatzaras, G.C. Sotiropoulos, et al. 2013. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 153 (6): 811–8. https://doi.org/10.1016/j.surg.2012.12.005.

Article  PubMed  Google Scholar 

Primrose, J.N., R.P. Fox, D.H. Palmer, et al. 2019. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology 20 (5): 663–673. https://doi.org/10.1016/s1470-2045(18)30915-x.

Article  CAS  PubMed  Google Scholar 

Rizzo, A., and G. Brandi. 2021. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Review of Gastroenterolgy & Hepatology 15 (5): 483–485. https://doi.org/10.1080/17474124.2021.1864325.

Article  CAS  Google Scholar 

Callahan, M.K., M.A. Postow, and J.D. Wolchok. 2016. Targeting T cell co-receptors for cancer therapy. Immunity 44 (5): 1069–78. https://doi.org/10.1016/j.immuni.2016.04.023.

Article  CAS  PubMed  Google Scholar 

Hoos, A. 2016. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nature Review Drug Discovery 15 (4): 235–47. https://doi.org/10.1038/nrd.2015.35.

Article  CAS  Google Scholar 

Kwilas, A.R., R.N. Donahue, K.Y. Tsang, and J.W. Hodge. 2015. mmune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenvironment. https://doi.org/10.14800/ccm.677.

Article  PubMed  PubMed Central  Google Scholar 

Kato, Y., K. Tabata, T. Kimura, et al. 2019. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One 14 (2).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taylor, M.H., C.H. Lee, V. Makker, et al. 2020. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. Journal of Clinical Oncology 38 (11): 1154–1163. https://doi.org/10.1200/jco.19.01598.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lidsky, M.E., Z. Wang, M. Lu, et al. 2022. Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies. NPJ  Precision Oncology 6 (1): 75. https://doi.org/10.1038/s41698-022-00320-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoy, S.M. 2020. Pemigatinib: first approval. Drugs 80 (9): 923–929. https://doi.org/10.1007/s40265-020-01330-y.

Article  PubMed  Google Scholar 

Rizzo, A., A.D. Ricci, G. Frega, A. Di Federico, and G. Brandi. 2021. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. Expert of Review Gastroenterology & Hepatology 15 (5): 567–574. https://doi.org/10.1080/17474124.2021.1911646.

Article  CAS  Google Scholar 

Abou-Alfa, G.K., V. Sahai, A. Hollebecque, et al. 2020. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. The Lancet Oncology 21 (5): 671–684. https://doi.org/10.1016/s1470-2045(20)30109-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lang, F., B. Schrörs, M. Löwer, Ö. Türeci, and U. Sahin. 2022. Identification of neoantigens for individualized therapeutic cancer vaccines. Nature reviews Drug discovery 21 (4): 261–282. https://doi.org/10.1038/s41573-021-00387-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gubin, M.M., X. Zhang, H. Schuster, et al. 2014. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (7528): 577–81. https://doi.org/10.1038/nature13988.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar